Effects of rosuvastatin vs. Simvastatin/ezetimibe on arterial wall stiffness in patients with coronary artery disease

Internal Medicine

Volumn 52, Issue 24, 2013, Pages 2715-2719

  Liu, Ban ^a   Che, Wenliang ^a   Yan, Hongwei ^a   Zhu, Weidong ^a   Wang, Hongbao ^b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Tongji University School of Medicine   (China)

Author keywords

Coronary artery disease; Low density lipoprotein cholesterol; Pulse wave velocity; ROCK activity; Statin

Indexed keywords

ALANINE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; EZETIMIBE PLUS SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYOSIN BINDING PROTEIN C; RHO KINASE; ROSUVASTATIN; TRIACYLGLYCEROL;

AGED; ARTERIAL STIFFNESS; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; FEMALE; HUMAN; INFLAMMATION; LIPID ANALYSIS; MALE; PLEIOTROPY; PLETHYSMOGRAPHY; PULSE WAVE; STENOSIS; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; AZETIDINES; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRIMIDINES; RHO-ASSOCIATED KINASES; SIMVASTATIN; SULFONAMIDES; TREATMENT OUTCOME; VASCULAR STIFFNESS;

EID: 84890484991     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.52.0731     Document Type: Article

References (29)

1. La Rosa JC, Hunninghake D, Bush D, et al. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The TaskForce on Cholesterol Issues, American Heart Association. Circulation 81: 1721-1733, 1990.
2. Teramoto T, Ohashi Y, Nakaya N, et al. Practical risk prediction tools for coronary heart disease in mild to moderate hypercholesterolemia in Japan: originated from the MEGA study data. Circ J 72: 1569-1575, 2008.
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339: 1349-1357, 1998.
4. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebocontrolled trial. Lancet 360: 7-22, 2002.
5. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 101: 207-213, 2000.
6. Nunes KP, Rigsby CS, Webb RC. RhoA/Rho-kinase and vascular diseases: what is the link? Cell Mol Life Sci 67: 3823-3836, 2010.
7. Zhou Q, Gensch C, Liao JK. Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease. Trends Pharmacol 32: 167-173, 2011.
8. Dong M, Yan BP, Yu CM. Current status of Rho-associated kinases (ROCKs) in coronary atherosclerosis and vasospasm. Cardiovasc Hematol Agents Med Chem 7: 322-330, 2009.
9. Mallat Z, Gojova A, Sauzeau V, et al. Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice. Circ Res 93: 884-888, 2003.
10. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 92: 152-160, 2003.
11. Moutzouri E, Liberopoulos E, Mikhailidis DP, et al. Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance. Int J Clin Pract 65: 1141-1148, 2011.
12. Kawano Y, Fukata Y, Oshiro N, et al. Phosphorylation of myosinbinding subunit (MBS) of myosin phosphatase by Rho-kinase in vivo. J Cell Biol 147: 1023-1038, 1999.
13. Nohria A, Prsic A, Liu PY, et al. Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis 205: 517-521, 2009.
14. Imanishi R, Seto S, Toda G, et al. High brachialankle pulse wave velocity is an independent predictor of the presence of coronary artery disease in men. Hypertens Res 27: 71-78, 2004.
15. Lunder M, Jani M, Jug B, et al. The effects of low-dose fluvastatin and valsartan combination on arterial function: A randomized clinical trial. Eur J Intern Med 23: 261-266, 2012.
16. Raison J, Rudnichi A, Safar ME. Effects of atorvastatin on aortic pulse wave velocity in patients with hypertension and hypercholesterolaemia: a preliminary study. J Hum Hyperten 16: 705-710, 2002.
17. McEniery C, Cockcroft J. Does Arterial Stiffness Predict Atherosclerotic Coronary Events? Adv Cardiol 44: 160-172, 2007.
18. Laurent S, Cockcroft J, Van Bortel L, et al. European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: Methodological issues and clinical applications. Eur Heart J 27: 2588-2605, 2006.
19. O'Rourke MF, Hashimoto J. Mechanical factors in arterial aging: A clinical perspective. J Am Coll Cardiol 50: 1-13, 2007.
20. Sugawara J, Hayashi K, Yokoi T, et al. Brachial-ankle pulse wave velocity: An index of central arterial stiffness? J Hum Hypertens 19: 401-406, 2005.
21. Liu PY, Liu YW, Lin LJ, et al. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rhoassociated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation 119: 131-138, 2009.
22. Goligorsky MS. Endothelial cell dysfunction: Can't live with it, how to live without it. Am J Physiol Renal Physiol 288: F871-F880, 2005.
23. Kones R. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease-a perspective. Drug Des Devel Ther 4: 383-413, 2010.
24. Ford ES, Giles WH, Myers GL, et al. Population distribution of high-sensitivity C-reactive protein among US men: findings from national health and nutrition examination survey 1999-2000. Clin Chem 49: 686-690, 2003.
25. Rifai N, Ridker PM. Population distributions of C-reactive protein in apparently healthy men and women in the United States: implication for clinical interpretation. Clin Chem 49: 666-669, 2003.
26. Wu DJ, Xu JZ, Wu YJ, et al. Effects of fasudil on early atherosclerotic plaque formation and established lesion progression in apolipoprotein E-knockout mice. Atherosclerosis 207: 68-73, 2009.
27. Hall A. G proteins and small GTPases: distant relatives keep in touch. Science 280: 2074-2075, 1998.
28. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358: 1431-1443, 2008.
29. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21: 1712-1719, 2001.